A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory DLBCL
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Vistusertib (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms TORCH
- 09 May 2018 Planned End Date changed from 1 Nov 2018 to 1 Apr 2019.
- 02 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.
- 27 Apr 2017 Status changed from active, no longer recruiting to completed.